The application of metformin in protecting chemotherapy-induced neuropathy
Phase 2
Recruiting
- Conditions
- Breast cancer.Carcinoma of breast, specialised type2C6Z
- Registration Number
- IRCT20151021024645N3
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Patients affected with breast cancer, based on the biopsy findings,
Exclusion Criteria
Active diabetic patients or those with a history of diabetes
The history of neuropathy or nerve damage
Anemia
The history of chemotherapeutic agent use
Hyperthyroidism or thyrotoxicosis
The patient with digestive problems who may less likely tolerate metformin
The patients with contraindications for metformin treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of neuropathy. Timepoint: At the beginning of the study and in cycles 2, 4, 6, 8, 10 and 12. Method of measurement: PNQ questionnaire, CTCAE questionnaire.;Laboratory parameters. Timepoint: At the beginning of the study (before the intervention), the end of cycle 6 and the end of cycle 12. Method of measurement: Laboratory evaluation.
- Secondary Outcome Measures
Name Time Method